New approaches to treating malignances with stem cell transplantation

Seminars in Oncology

Volumn 27, Issue 5, 2000, Pages 524-530

  Margolis, J ^a   Borrello, I ^a   Flinn, I W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; RITUXIMAB;

ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER REGRESSION; CANCER THERAPY; CONFERENCE PAPER; HEMATOLOGIC DISEASE; HUMAN; IMMUNOTHERAPY; LEUKAPHERESIS; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; LEUKAPHERESIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033794142     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
2. Graft-versus-tumor response
3. A 'graft-versus-leukemia reaction' in man?
4. Abrupt cessation of immunosuppression in a patient with persistent acute lymphoblastic leukemia following allogeneic transplantation
5. Graft-versus-leukemia reactions after bone marrow transplantation
6. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
7. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party
8. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes
9. p53-Dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32b
10. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
11. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
12. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
13. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
14. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
15. Transplant-Lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
16. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
17. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine and mycophenolate mofetil
18. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow transplantation in CML
19. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
20. Pharmacological purging of bone marrow
21. Autologous bone marrow transplantation in acute myeloid leukemia: The University of Minnesota experience
22. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia
23. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen
24. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: A follow-up report
25. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide
26. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia
27. Improved outcomes for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow
28. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged bone marrow
29. The antitumor effects of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL cell lines
30. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
31. In vivo purging with rituximab during stem cell transplantation for indolent lymphoma
32. In vivo purging of circulating CD34+ progenitor cells in low-grade lymphoma with rituximab and high-dose chemotherapy
33. Induction of graft-versus-host disease after autologous bone marrow transplantation
34. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia
35. Graft-versus-host disease in cyclosporine A treated rats after syngeneic and autologous bone marrow reconstitution
36. Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease
37. Successful in-vitro graft-versus-tumor effect against an Ia bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat
38. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer
39. Interferon potentiates the antitumor effect of cyclosporine-induced autoimmunity
40. Cancer vaccines
41. Tolrance an cancer: A critical issue in tumor immunology
42. Alteration in signal transduction molecules in T lymphocytes from tumor-bearing mice
43. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: A strategy for using autologous marrow as an anti-tumor therapy
44. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing
45. Sustaining the graft vs tumor effect through post transplantation immunization with GM-CSF producing tumor vaccines